Filtered By:
Specialty: Cancer & Oncology
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 42 results found since Jan 2013.

Managing the Risks of Cardiac Therapy in Cancer Patients
The purpose of this review was to highlight the more commonly used cardiac medications that should be closely monitored or possibly discontinued during cancer therapy. Often, older cancer patients are taking multiple pharmacotherapy agents for the treatment or prevention of cardiac disease when they face decisions about cancer treatment. Concurrent administration of drugs can result either in increased toxicity or decreased efficacy of either therapy. The benefits of the cardiac medications must be weighed against the effects of cancer therapy, and the role of drug metabolism also must be considered. For example, the benef...
Source: Seminars in Oncology - April 1, 2013 Category: Cancer & Oncology Authors: Carol L. Chen, Rekha Parameswaran Tags: Marc L. Schwartz, ME, Guest Editor Source Type: research

Estimates of benefits and harms of prophylactic use of aspirin in the general population
Conclusions Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit–harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening–eradication before starting aspirin prophylaxis.
Source: Annals of Oncology - December 17, 2014 Category: Cancer & Oncology Authors: Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., Law, M., Meyskens, F., Rothwell, P. M., Senn, H. J., Umar, A. Tags: reviews Source Type: research

USPSTF publishes recommendation on taking aspirin to prevent heart attack, stroke, and colorectal cancer
(American College of Physicians) The US Preventive Services Task Force recommends that people who are 50-69 years old, have increased risk of cardiovascular disease (CVD), and who are not at increased risk for bleeding, consider taking aspirin for primary prevention of CVD and colorectal cancer. The full recommendation and evidence reviews are published in Annals of Internal Medicine.
Source: EurekAlert! - Cancer - April 11, 2016 Category: Cancer & Oncology Source Type: news

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy
Conclusion The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery.
Source: Neuro-Oncology - June 6, 2016 Category: Cancer & Oncology Authors: Saran, F., Chinot, O. L., Henriksson, R., Mason, W., Wick, W., Cloughesy, T., Dhar, S., Pozzi, E., Garcia, J., Nishikawa, R. Tags: Clinical Investigations Source Type: research

Use and Misuse of Aspirin in Primary Cardiovascular Prevention.
Abstract The use of low-dose aspirin in primary prevention of cardiovascular (CV) events in healthy or apparently healthy people is a widely debated topic. Many arguments indicate that "primary prevention" is only a conventional definition and that the transition from primary to secondary prevention represents a continuum of increasing levels of CV risk. Although there are no direct proofs of a different efficacy of aspirin at different CV risk levels, in low-risk populations aspirin will appear to be less efficient. In fact, the lower number of events occurring in patients at low risk yields lower absolute number...
Source: Clinical Colorectal Cancer - May 6, 2017 Category: Cancer & Oncology Authors: Coccheri S Tags: Clin Med Insights Cardiol Source Type: research

Aspirin for Primary Prevention.
Abstract Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable unce...
Source: Clinical Colorectal Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Richman IB, Owens DK Tags: Med Clin North Am Source Type: research

Unusual Techniques for Preserving Surgical and Oncologic Safety in Hepatectomy of Advanced Adrenal Malignancy with Vena Cava and Liver Invasion
We report herein three cases of major hepatectomy with IVC invasion and discuss several surgical tips.Patients and MethodsFrom March 2011 to February 2014, we retrospectively reviewed three cases of adrenal malignancy with liver and IVC invasion. Based on the severity of the malignant tumor, each case illustrates a different method to address surgical complications and maintain oncologic safety. Case 1: A 34-year-old woman was diagnosed with adrenocortical tumor during medical examination. Tumor invaded the right lobe of the liver and very close to the IVC. Fortunately, there was little thrombosis inside the IVC; we perfor...
Source: Annals of Surgical Oncology - September 6, 2018 Category: Cancer & Oncology Source Type: research

Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
AbstractPurpose of ReviewThe anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients.Recent FindingsThere are a range of indications for therapeutic anticoagulation in cancer patients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi. Certain cancer...
Source: Current Oncology Reports - April 3, 2019 Category: Cancer & Oncology Source Type: research

A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding.
CONCLUSION: Although these agents have been marketed for five years (idarucizumab) and two years (andexanet alfa) respectively, and despite guidelines considering antidotes as first-line agents in treating life-threatening hemorrhage when available, these antidotes seem to gain access very slowly in the clinical practice. Cost, logistical aspects and need for plasma level determination of DOAC for an accurate therapeutic use probably have an impact on this phenomenon.. An expert multidisciplinary bleeding team should be established so as to implement international guidelines based on local resources and organization. ...
Source: Reviews on Recent Clinical Trials - June 23, 2020 Category: Cancer & Oncology Authors: Ojetti V, Saviano A, Brigida M, Saviano L, Migneco A, Franceschi F Tags: Rev Recent Clin Trials Source Type: research

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Conclusion: In cancer patients with AF, NOAC were associated with significant reduced IS/SE, major bleeding, and ICH compared to warfarin.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Tung Huang, Wen-Ching Lan, Michael Wu, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu, Ming-Shien Wen, Chi-Ching Kuo, Shang-Hung Chang Tags: Research Paper Source Type: research

Anticoagulation for atrial fibrillation in active cancer
Oncol Lett. 2022 Apr;23(4):124. doi: 10.3892/ol.2022.13244. Epub 2022 Feb 17.ABSTRACTAtrial fibrillation (AF) may often pre-exist in patients with newly diagnosed cancer or occur with increased frequency shortly after cancer diagnosis. Patients with active cancer and AF have a particularly high risk of thromboembolic complications, as both conditions carry a risk of thrombosis. Thromboembolic risk is determined by several factors, including advanced age, sex (females), cancer histology (adenocarcinomas), location (e.g., pancreas, stomach), advanced stage, anticancer regimens (e.g., platinum compounds, anti-angiogenic thera...
Source: Oncology Letters - March 9, 2022 Category: Cancer & Oncology Authors: Dimitrios Farmakis Pavlos Papakotoulas Eleni Angelopoulou Theodoros Bischiniotis George Giannakoulas Panagiotis Kliridis Dimitrios Richter Ioannis Paraskevaidis Source Type: research